SCHEMBL2261171

SCHEMBL2261171

COc1ccc(S(=O)(=O)Nc2cc(CO)ccc2Cl)cc1OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.60
TP53 P04637 1/20 0.60
LMNA P02545 4/20 0.55
GAA P10253 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
KEAP1 Q14145 1/20 0.54
NFE2L2 Q16236 1/20 0.54
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
MAPK1 P28482 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
HTT P42858 1/20 0.52
PKM P14618 2/20 0.52
TSHR P16473 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C19 P33261 1/20 0.51
CYP2C9 P11712 1/20 0.50
CA12 O43570 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4664207 0.86 ALDH1A1 (0.55) ALDH1A1TP53LMNAGAAL3MBTL1
SCHEMBL2260544 0.81 ALDH1A1 (0.62) ALDH1A1TP53LMNAGAAL3MBTL1
SCHEMBL2260761 0.80 ALDH1A1 (0.58) ALDH1A1TP53LMNAGAAL3MBTL1
SCHEMBL2261232 0.80 ALDH1A1 (0.58) ALDH1A1TP53LMNAGAAL3MBTL1
SCHEMBL2261153 0.79 ALDH1A1 (0.61) ALDH1A1TP53LMNAGAAL3MBTL1
SCHEMBL2263708 0.79 ALDH1A1 (0.61) ALDH1A1TP53LMNAGAAL3MBTL1
SCHEMBL12786357 0.78 ALDH1A1 (0.54) ALDH1A1TP53LMNAL3MBTL1KMT2A
SCHEMBL27766045 0.77 ALDH1A1 (0.58) ALDH1A1TP53LMNAGAAL3MBTL1
SCHEMBL12786364 0.76 LMNA (0.53) ALDH1A1TP53LMNAL3MBTL1KMT2A
SCHEMBL13028519 0.75 TP53 (0.49) ALDH1A1TP53LMNANPSR1FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101460453-B Novel sulfonamide compounds ACTELION PHARMACEUTICALS LTD 2012-10-03 CN disclosed
US-8003654-B2 N-glycinsulfonamide derivatives and uses as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2011-08-23 US disclosed
US-20090275588-A1 NOVEL SULFONAMIDE COMPOUNDS ACTELION PHARMACEUTICALS LTD. (CH) 2009-11-05 US disclosed
CN-101460453-A Novel sulfonamide compounds ACTELION PHARMACEUTICALS LTD (CH) 2009-06-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275588-A1 NOVEL SULFONAMIDE COMPOUNDS HCRTR2, HCRTR1, NPSR1 ALDH1A1 2824/4885TP53 4868/4885LMNA 4196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.